S-cubed Global
S-Cubed
  • S-CUBED Logo
  • Services
    • Biometrics
    • SAS & Statistical Programming
    • Biostatistics
    • CDISC
    • Regulatory Affairs
  • News & Articles
  • About Us
    • Our Stories
    • Career
  • Contact
    • Privacy at S-cubed
  • Search
Select Page

CDISC 360 Project and the A3 Suite

Published 24-07-2019

Building new tools needs clear vision. Kirsten Langendorf explains the shared vision of the CDISC 360 Project and the A3 Suite.

Click on any image to enlarge (with thanks to CDISC for slides and logo). Contact us here for further information. 

The A3 suite (Figure 1), which contains an MDR and a Study Workbench (SWB), has been developed (and is being continuously improved) with the same vision in mind as the CDISC 360 project. Much of the vision of the CDISC 360 project is alive and already working today in the A3 suite.

A3 Suite: MDR & SWB

Figure 1: Components of A3 Suite including future extensions

About the CDISC 360 Project

Looking at the description of the CDISC 360 project description the purpose is to: “support standards-based, metadata-driven automation across the end-to-end clinical research data lifecycle and represents a significant next step toward realizing an increased return on investment in standards implementation that our stakeholders expect – substantially improved efficiency, consistency, and re-usability.”

Three use cases will be assessed as part of the CDISC 360 project. The A3 suite is currently able to demonstrate many of these automated functions and thereby support the vision of the CDISC 360 project. These will be described below.

Use Case 1 (Populate MDR)

Create end-to-start specification – Demonstrate the ability to produce a standards-based, machine-readable specification for the data and analysis artefacts to be created in the study, see Figure 2.

CDISC 360: Use Case 1

Figure 2: End-2-end MDR content

A3 MDR Supporting Use Case 1

The overall functionality of the A3 MDR is:

A3 MDR Functionality

  • CDISC terminology and sponsor defined terminology
  • CDISC models and IGs (e.g. SDTM/SDTMIG, ADaM/ADaMIG) and sponsor versions of the CDISC models (domains)
  • Biomedical concepts
    • definition of data to be collected in relation to relation to procedures being conducted on the subject in a study. e.g. the measurement of systolic blood pressure and the additional attributes (standing/sitting, unit)
  • Standard Case Report Forms (CRFs)
    • Collection of Biomedical concepts or questions on a logical page including instructions to user for completing the form.
Impact Assessment

In the MDR, the impact of the managed items (terminology, BCs, forms and domains), when a new model or a new terminology is being introduced, can be assessed. Based on the impact assessment, a new version of biomedical concepts, forms and sponsor defined terminology may be required.

The standards are made available for the other tools (e.g. the A3 SWB) for re-use and to ensure standardization of data collection.

Being built on graph technology, the different standards and metadata is linked together behind the scenes.

This allows for easy (push button) impact assessment (see Figure 3.1 & 3.2), changes to terminology (see Figure 4), and obtaining the annotated CRF (see Figure 5) for a standard form in the MDR by a simple push of a button – no annotation needed (see figure 6).

CDISC Terminology

Figure 3.1 Impact Assessment

Impact Analysis

Figure 3.2: Impact Assessment

Creating an aCRF using the MDR

Figure 4: Terminology Changes

A3 MDR to create aCRF

Figure 5: Push Button aCRF

Annotated CRF

Figure 6: Annotate CRF of standard form in the MDR

A3 MDR & SWB Supporting Use Case 2 (Specific Study Metadata)

Generate start-to-end metadata – Demonstrate the ability to generate study-specific artefacts given the standards specification from Use Case 1,  see Figure 7 and Figure 8.

CDISC 360 Project End to End

Figure 7: Select Study Metadata from MDR

CDISC 360 Project Study Build

Figure 8: Study Build based on Study Metadata

The A3 SWB uses the A3 MDR metadata to specify what to collect on a study. The overall functionality of the A3 SWB is:

A3 Study Workbench Using the MDR

The A3 SWB is a tool designed with the Data Manager in mind to help setting up data collection for studies in an organisation. In the A3 SWB, metadata on what data to collect is specified, see Figure 9.

A3 Study Workbench to create an SoA

Figure 9 SoA for a sample study

The A3 SWB uses the forms defined in A3 MDR. The output of this process is one or more export file(s) to the EDC system (see Figure 10), facilitating a quicker EDC system setup for the study, and specification to other data collections means (Lab and ePRO).

A3 SWB Forms defined in A3 MDR - Export to EDC

Figure 10 EDC export files and export for define.xml by push of a button

The CRF can be displayed, printed as a report or exported for e.g. EDC load. In addition, the annotated CRF (aCRF) can be displayed/exported (see Figure 11)  and the define.xml can be generated and exported (see Figure 10). The define.xml picks all relevant metadata from the forms selected to populate domains, value level metadata and controlled terms, see Figure 12.

aCRF exported and displayed

Figure 11 Generated aCRF for the sample study(excerpt)

Define.xml uses metadata to create domains

Figure 12 Automated metadata for define.xml

The support for the trial design domains will be available in a future release.

A3 SWB & MDR Supporting Use Case 3 (Study metadata-driven data transformation)

Transform data start-to-end – Demonstrate the ability to process data and execute data transformations given the study specification from Use Case 2, see Figure 13.

CDISC 360 Use Case 3 Study Metadata-driven data transformation

Figure 13 Automate data transformation using study metadata

This end-to-end use case is in alignment with the A3 vision. However, being built on graph technology, we envision that the actual data will co-exist with the metadata for the study. Viewing and using data, e.g. in BI and SCE tools, will then access the data from the graph by a query. Putting the subject data together with the study metadata has been demonstrated earlier in this blog.

The CDISC 360 project is trying to break down the data silos that are often seen in organisations to ensure better data and more effective data processing and traceability. This is very much in alignment with the vision of the A3 Suite. If we have sparked your interest, please get in touch and we can discuss our solution to the challenges in your organisation. 



Tags: A3 MDR A3 Study Workbench A3 Suite Biomedical Concepts CDISC CDISc 360 Project End to End MDR Metadata Study Build

Archive

2023

  • S-cubed Denmark (ApS) acquired by Phastar
  • EDQM Launches CEP 2.0
  • Q2 2023 Newsletter – What’s New in Clinical Development Practices & Regulations
  • Q1 2023 Newsletter – What’s New in Clinical Development Practices & Regulations

2022

  • Q4 2022 Newsletter – Regulations & ICH Guidelines; FDA Guidelines; Clinical Trial Data
  • 1st Dec 2022 – Launch of Phase 2 of the Simultaneous National Scientific Advice (SNSA) Pilot
  • Regulations & ICH Guidelines; Inspections; Initiatives across the World; RWD/RWE
  • Titanium dioxide in Medicinal Products
  • Regulations & ICH Guidelines; EU/UK/US Guidance; RWD/RWE
  • Combined Review Process for Clinical Trials
  • EU Clinical Trial Regulation
  • COVID-19, New Regulations: Latest Industry Update

2021

  • Clinical Trial Guidance and Legislation
  • Regulatory Guidance and News
  • Clinical Trials Update: COVID-19
  • Mark Baillet – A View from the Biometrics Managing Director’s Office
  • Swiss-exit, Turkey-exit, BREXIT and Medical Device Regulation
  • EU Medical Devices Regulation: 26 May 2021
  • World Kidney Day – A Personal Story
  • S-cubed Biometrics’ Mark Baillet: Why Choose Us?
  • Regulations & Guidance: Clinical Trials
  • Women in Science: A Celebration

2020

  • Clinical Trials News and Regulations
  • MHRA Post-Transition Period Information
  • MHRA Submissions – The UK submissions portal from 01 January 2021
  • Virtually Standing: The CDISC and PHUSE Challenge
  • Autumn Events with S-cubed & A3
  • Clinical Trials News from around the Globe
  • Lies, Damned Lies & Statistics
  • Covidgraph: One Nerd’s Response to the Pandemic
  • EMA Publishes Updated Guidance on Nitrosamines Impurities
  • Down the SDTM Rabbit Hole – Scratching an Itch
  • Marketing Authorisation Holder GMP-related Responsibilities
  • Clinical Development Practices & Regulations
  • A3ccelerate, Social Distancing, and Toblerone
  • Supporting Clients using Full Service CROs
  • COVID-19: European Medicines Agency Updates
  • CDISC Interchange 2020 Goes Virtual and We’ll Be There!
  • Nitrosamine Risk Evaluation for Marketing Authorisation Holders
  • Clinical Trial Regulation, ICH E6(R2) & Brexit
  • Clinical Monitoring – What We’ve Learned
  • CDISC Terminology – Gain control using the A3 Community MDR
  • MAH Nitrosamine Risk Evaluation update – 1 month to go
  • Simultaneous National Scientific Advice (SNSA)
  • Nitrosamine MAH Risk Assessment – Two Months to Go
  • Finalised ICH E9(R1) Estimands and Sensitivity Analysis Guidance

2019

  • Growth, a new office and successful software!
  • Nitrosamines, TOPRA, Drug Development News
  • A3 Community MDR Now Launched
  • Using Real World Data to Enhance Pharmaceutical Development
  • Pharmaceutical Industry Events this Autumn
  • Global Harmonisation of Clinical Trials
  • Protocol writing is changing – Estimands (ICH E9(R1))
  • CDISC 360 Project and the A3 Suite
  • CDISC, PhUSE, DADM – Events Update
  • Statistics and Machine Learning – Cause for concern or excitement?
  • Latest News in Clinical Development Practices and Regulations
  • 10 Years of S-cubed at CDISC: The Interchange 2019
  • S-cubed Announces A3 Informatics Merger and New Partners
  • Celebrating 10 Years of Regulatory Affairs and Quality Assurance
  • Data Silos, Demos, Discussions at PhUSE
  • Brexit, EMA, FDA & Global Regulatory News
  • PhUSE Keynote – A Cautionary Tale
  • Regulatory Affairs & Quality Assurance: Copenhagen
  • PhUSE US Connect & CDISC
  • SME Day at EMA – Part 3
  • Qlik Specialization Status Awarded to S-cubed
  • SME Day at the EMA – Part Two
  • SME Day at the EMA – Part One
  • Brexit Update, Clinical Trial Data Sharing, & more

2018

  • Qlik Team on Tour – Are you part of the Data Revolution?
  • EMA, PhUSE, Bioforward and the latest Staff Update
  • PhUSE Connect and future CDISC Training at S-cubed
  • The Impact of Brexit on Pharmaceuticals in the UK – UPDATE
  • Brexit, access to medicines, data & data sharing
  • S-cubed: Building a Unique Culture
  • The Impact of BREXIT on Pharmaceuticals in the UK
  • Six months to go! Will you be ready for Serialisation by February 2019?
  • BREXIT, PATIENT PERSPECTIVES, DATA SHARING in our Industry Insights for Q2
  • S-cubed on the road to success!
  • S-cubed Presenting at PhUSE US Connect in RTP

Tags

A3 MDR A3 Study Workbench A3 Suite Biomedical Concepts Biometrics Brexit CDISC Clinical Trial Clinical Trial Authorisations Clinical Trial Regulation Controlled Terminology COVID-19 Data Analysis Data Analytics data management Data Protection Data Quality data science EMA EudraCT Events FDA Graph Technology ICH Industry Insights Linked Data Marketing Authorisation Marketing Authorisation Holder MDR Medical Devices Medical Monitoring MHRA Nitrosamines Pharmacovigilance PhUSE Protocol Qlik Qlik Sense Real World Data Real World Evidence Regulatory Affairs SDTM SME Statistical Programming Statistics

S-CUBED APS
COPENHAGEN

Lautrupsgade 7, 1. tv.,
2100 Copenhagen Ø, Denmark
Tel: +45 31 45 29 16
Email: info@s-cubed-global.com

Related Articles

Marketing Authorisation Holder GMP-related Responsibilities

An overview of PRIME, Breakthrough Therapy & Fast Track procedures

Optimising the path to commercialisation; Who can help and when?

S-Cubed

S-CUBED LTD
OXFORD

Boston House,
Grove Business Park
Wantage, OX12 9FF, UK
Tel: +44 1235 77 22 60
Email: info@s-cubed-global.com

S-CUBED BIOMETRICS LTD
OXFORD

99 Park Drive, Milton Park
Abingdon, OX14 4RY
UK
Tel: +44 1235 84 15 27
Email: info@s-cubed-global.com

Instagram LinkedIn Twitter Vimeo

© S-cubed 2022